The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Abstract
OBJECTIVE: The "atypical" profile of the new antipsychotics clozapine, olanzapine, quetiapine, and risperidone has been linked to combined antagonism of serotonin 2 (5-HT(2)) and dopamine 2 (D(2)) receptors. Although amisulpride is a highly selective D(3)/D(2) receptor antagonist, it is assumed to have atypical properties as well. The purpose of this article was to compare the atypical profile of amisulpride with that of the 5-HT(2)/D(2) antagonists. METHOD: Randomized controlled trials that compared amisulpride with conventional antipsychotics or placebo for patients with schizophrenia were identified and included in a meta-analysis. The mean effect sizes found for amisulpride were compared with those of an updated meta-analysis of the 5-HT(2)/D(2) antagonists. RESULTS: Eighteen randomized controlled trials of amisulpride (N=2,214) were found. In 11 studies of acutely ill patients it proved to be consistently more effective than conventional antipsychotics for global schizophrenic symptoms (measured with the Brief Psychiatric Rating Scale) and negative symptoms. Amisulpride is to date the only atypical antipsychotic for which several studies of patients suffering predominantly from negative symptoms have been published. In four such studies amisulpride was significantly more effective than placebo. Three small studies with conventional antipsychotics as comparators showed only a trend in favor of amisulpride in this regard. Amisulpride was associated with clearly lower use of antiparkinsonian medication and with fewer dropouts due to adverse events than conventional antipsychotics. CONCLUSIONS: These results cast some doubt on the notion that combined 5-HT(2)/D(2) antagonism is the reason that the newer antipsychotic medications are effective for negative symptoms and have fewer extrapyramidal side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations
Andreasen, N. C. (1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291496 · Cited by 1,530
A simple, general purpose display of magnitude of experimental effect.
Rosenthal, R., & Rubin, D. B. (1982) · Journal of Educational Psychology · doi:10.1037//0022-0663.74.2.166 · Cited by 1,229
Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,062
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Self-citationDo Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Atypical antipsychotics and weightgain — a systematic review
Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 433
The Role of Serotonin in Schizophrenia
Bleich, A., Brown, S.-L., Kahn, R., & van Praag, H. M. (1988) · Schizophrenia Bulletin · doi:10.1093/schbul/14.2.297 · Cited by 371
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 305
Olanzapine Compared With Chlorpromazine in Treatment-Resistant Schizophrenia
Conley, R. R., Tamminga, C. A., Bartko, J. J., Richardson, C., Peszke, M., Lingle, J., Hegerty, J., Love, R., Gounaris, C., & Zaremba, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.914 · Cited by 245
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
Boyer, P., Lecrubier, Y., Puech, A. J., Dewailly, J., & Aubin, F. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.1.68 · Cited by 229
Perrault, G., Depoortere, R., Morel, E., Sanger, D. J., & Scatton, B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36394-3 · Cited by 229
Kramer, M. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180085011 · Cited by 199
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Loo, H., Poirier-Littre, M.-F., Theron, M., Rein, W., & Fleurot, O. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride
Danion, J.-M., Rein, W., Fleurot, O., & the Amisulpride Study Group (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.610 · Cited by 185
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H.-J., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
Dropout rates in randomised antipsychotic drug trials
Wahlbeck, K., Tuunainen, A., Ahokas, A., & Leucht, S. (2001) · Psychopharmacology · doi:10.1007/s002130100711 · Cited by 167
Self-citationOlanzapine: a basic science update
Bymaster, F. P., Perry, K. W., Nelson, D. L. G., Wong, D. T., Rasmussen, K., Moore, N. A., & Calligaro, D. O. (1999) · The British Journal of Psychiatry · doi:10.1192/s0007125000293653 · Cited by 154
Risperidone in Treatment-Refractory Schizophrenia
Wirshing, D. A., Marshall, B. D., Green, M. F., Mintz, J., Marder, S. R., & Wirshing, W. C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1374 · Cited by 148
Möller, H., Müller, H., Borison, R. L., Schooler, N. R., & Chouinard, G. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191543 · Cited by 147
Copolov, D., Link, C. G. G., & Kowalcyk, B. B. (2000) · Psychological Medicine · doi:10.1017/s0033291799001476 · Cited by 144
Puech, A. J., Fleurot, O., Rein, W., & Amisulpride Study Group (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10044.x · Cited by 143
Improvement of some schizophrenic deficit symptoms with low doses of amisulpride
Martinot, M. P., Lecrubier, Y., Martinot, J., & Aubin, F. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.130 · Cited by 142
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia
Colonna, L., Saleem, P., Dondey-Nouvel, L., & Rein, W. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015010-00002 · Cited by 139
Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol
Möller, H. ‐., Boyer, P., Fleurot, O., & Rein, W. (1997) · Psychopharmacology · doi:10.1007/s002130050361 · Cited by 139
Wetzel, H., Gründer, G., Hillert, A., Philipp, M., Gattaz, W. F., Sauer, H., Adler, G., Schröder, J., Rein, W., & Benkert, O. (1998) · Psychopharmacology · doi:10.1007/s002130050614 · Cited by 129
Amisulpride: from animal pharmacology to therapeutic action
Scatton, B., Claustre, Y., Cudennec, A., Oblin, A., Perrault, G., Sanger, D. J., & Schoemaker, H. E. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705002-00006 · Cited by 127
Blin, O., Azorin, J. M., & Bouhours, P. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199602000-00007 · Cited by 117
Seroquel: electrophysiological profile of a potential atypical antipsychotic
Goldstein, J. M., Litwin, L. C., Sutton, E. B., & Malick, J. B. (1993) · Psychopharmacology · doi:10.1007/bf02244924 · Cited by 114
Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R. A., Carlsson, A., & Tamminga, C. A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00030-9 · Cited by 104
Speller, J. C., Barnes, T. R. E., Curson, D. A., Pantelis, C., & Alberts, J. (1997) · The British Journal of Psychiatry · doi:10.1192/bjp.171.6.564 · Cited by 103
Carrière, P., Bonhomme, D., & Lempérière, T. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00401-6 · Cited by 100
Clinical update on amisulpride in deficit schizophrenia
Rein, W., & Turjanski, S. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705002-00005 · Cited by 93
Risperidone versus Haloperidol on Secondary Memory: Can Newer Medications Aid Learning?
Kern, R. S., Green, M. F., Marshall, B. D., Wirshing, W. C., Wirshing, D. A., McGurk, S. R., Marder, S. R., & Mintz, J. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033375 · Cited by 93
Volonté, M., Monferini, E., Cerutti, M., Fodritto, F., & Borsini, F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010182.x · Cited by 88
Delcker, A., Schoon, M., Oczkowski, B., & Gaertner, H. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014494 · Cited by 79
Liu, S. K. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00137-2 · Cited by 76
Negative symptoms in schizophrenia: considerations for clinical trials
Möller, H. ‐., van Praag, H. M., Aufdembrinke, B., Bailey, P., Barnes, T. R. E., Beck, J., Bentsen, H., Eich, F. X., Farrow, L. R., Fleischhacker, W. W., et al. (1994) · Psychopharmacology · doi:10.1007/bf02244775 · Cited by 71
Saletu, B., Kufferle, B., Grünberger, J., ldes, P. F. O., Topitz, A., & Anderer, P. (2008) · Neuropsychobiology · doi:10.1159/000119075 · Cited by 67
Berk, M., Brook, S., & Trandafir, A. I. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199905002-00005 · Cited by 51
New Dimensions in the Pharmacologic Treatment of Schizophrenia and Related Psychoses
Buckley, P. F. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb04314.x · Cited by 42
What is an atypical antipsychotic?
Reynolds, G. P. (1997) · Journal of Psychopharmacology · doi:10.1177/026988119701100301 · Cited by 32
Aktuelle Bewertung neuer/atypischer Neuroleptika
Møller, H. J. (2000) · Der Nervenarzt · doi:10.1007/s001150050567 · Cited by 32
Allan, E. R., Sison, C., Alpert, M., Connolly, B., & Crichton, J. (1998) · PubMed · Cited by 29
See, R. E., Fido, A. A., Maurice, M., Ibrahim, M. M., & Salama, G. M. S. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00199-1 · Cited by 27
Berk, S. B. M. (2000) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500050518316 · Cited by 19
Berk, M., Brook, S., & Nur, F. (2000) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500009177999 · Cited by 17
A Double Blind Comparison of Amisulpride vs. Haloperidol in Acute Schizophrenic Patients
Klein, H., Dieterle, D., Rüther, E., Eben, E., Nedopil, N., & Hippius, H. (1985) · Springer eBooks · doi:10.1007/978-1-4613-2363-1_106 · Cited by 12
Cited by
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
“dopamine D2/D3-receptor antagonist amisulpride—one of the most effective drugs currently in use for the treatment of schizophrenia.(30) Patients undergoing either cannabidiol or amisulpride treatment showed significant clinical improvement, assessed by the reduction in PANSS total score (Po0.”
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13306-5 · Cited by 725
Self-citation
Metadata
- Authors
- Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W.
- Venue
- American Journal of Psychiatry
- Published
- 2002-02-01
- Volume
- 159
- Issue
- 2
- Pages
- 180-190
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2115125760
- Cited by
- 470
- References
- 53
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.